Published on
Oct 20, 2025
<![CDATA[Verzenio and Kisqali Deliver Positive Long-Term Results in Early Breast Cancer Trials]]>
Topline findings Verzenio plus endocrine therapy reduced the risk of death by 15.8% versus ET alone in high-risk HR+/HER2– early breast cancer. Seven-year overall survival rate reached 86.8% with Verzenio versus 85% with ET alone. Kisqali plus ET …
Source:
Applied Clinical Trials
-
Pending
